ERYtech Pharma announces that FDA has granted an Orphan Drug Designation (ODD) for GRASPA®, the company's lead product in Acute Lymphoblastic Leukaemia. Pierre-Olivier Goineau, Co-Founder and COO comments: ''Following the ODD granted by EMEA for the use of GRASPA for ALL in Europe, this ODD granted by FDA extends other viable exclusivity to the United States market. It also confirms the similar llc.cite this source roget's ii: the new lexicon



if (lexico_globals.googleafc.ads.content.length)
{
document.write(lexico_globals.googleafc.ads.contenttop);
document.write(lexico_globals.googleafc.ads.sponsoredlinks);
document.write(lexico_globals.googleafc.ads.content[2]);
document.write("") of GRASPA as a medicinal product by both agencies." "Discussions are ongoing with US Key Opinion Leaders to initiate new clinical trials with GRASPA...

More: - From the site